Peer-reviewed veterinary case report
Osaterone acetate reduces prostate size and symptoms in dogs with BPH
By Socha, P et al.·Published in Polish journal of veterinary sciences·2018·Department of Animal Reproduction with Clinic·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The effects of osaterone acetate on clinical signs and prostate volume in dogs with benign prostatic hyperplasia.
- Species:
- dog
Plain-English summary
A group of 23 dogs with benign prostatic hyperplasia (BPH), a condition that can cause difficulty urinating and other discomforts, were treated with osaterone acetate (Ypozane). After just one week of treatment, the dogs showed a significant improvement in their symptoms, with many experiencing complete relief by the end of the 28-day trial. Additionally, the size of their enlarged prostates decreased significantly, returning to nearly normal levels. This treatment proved effective in managing BPH in dogs, helping them feel much better.
People also search for: dog prostate problems treatment · osaterone acetate for dogs · BPH symptoms in dogs
Abstract
A clinical trial was performed to evaluate the therapeutic efficacy of osaterone acetate (OSA) in the treatment of benign prostatic hyperplasia (BPH) in dogs. Osaterone acetate (Ypozane, Virbac) was administered orally at a dose of 0.25 mg/kg body weight once a day for seven days to 23 dogs with BPH. During the 28-day trial, the dogs were monitored five times for their clinical signs and prostate volume. The OSA treatment promoted rapid reduction of clinical scores to 73.2% on day 7 and to 5.9% on day 28 (p⟨0.05). Osaterone acetate induced the complete clinical remission in approximately 83.0% of the dogs on day 28. The prostate volume regressed to 64.3% of the pretreatment volume after two weeks of the treatment (p⟨0.05) and to 54.7% at the end of the trial (p⟨0.05). In conclusion, OSA quickly reduced clinical signs and volume of the prostate glands in dogs with BPH.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30605276/